Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response.

Liston A, Kohler RE, Townley S, Haylock-Jacobs S, Comerford I, Caon AC, Webster J, Harrison JM, Swann J, Clark-Lewis I, Korner H, McColl SR.

J Immunol. 2009 Mar 1;182(5):3121-30. doi: 10.4049/jimmunol.0713169.

2.

Antagonism of the chemokine receptors CXCR3 and CXCR4 reduces the pathology of experimental autoimmune encephalomyelitis.

Kohler RE, Comerford I, Townley S, Haylock-Jacobs S, Clark-Lewis I, McColl SR.

Brain Pathol. 2008 Oct;18(4):504-16. doi: 10.1111/j.1750-3639.2008.00154.x. Epub 2008 Apr 11.

PMID:
18422759
3.

Probing receptor binding activity of interleukin-8 dimer using a disulfide trap.

Rajarathnam K, Prado GN, Fernando H, Clark-Lewis I, Navarro J.

Biochemistry. 2006 Jun 27;45(25):7882-8.

4.

Self-malonylation is an intrinsic property of a chemically synthesized type II polyketide synthase acyl carrier protein.

Arthur CJ, Szafranska A, Evans SE, Findlow SC, Burston SG, Owen P, Clark-Lewis I, Simpson TJ, Crosby J, Crump MP.

Biochemistry. 2005 Nov 22;44(46):15414-21.

PMID:
16285746
5.

The CC chemokine ligand, CCL2/MCP1, participates in macrophage fusion and foreign body giant cell formation.

Kyriakides TR, Foster MJ, Keeney GE, Tsai A, Giachelli CM, Clark-Lewis I, Rollins BJ, Bornstein P.

Am J Pathol. 2004 Dec;165(6):2157-66.

6.

Control of Salmonella dissemination in vivo by macrophage inflammatory protein (MIP)-3alpha/CCL20.

Fahy OL, Townley SL, Coates NJ, Clark-Lewis I, McColl SR.

Lab Invest. 2004 Nov;84(11):1501-11.

7.

NMR structure of CXCR3 binding chemokine CXCL11 (ITAC).

Booth V, Clark-Lewis I, Sykes BD.

Protein Sci. 2004 Aug;13(8):2022-8.

8.

Inhibition of generation of cytotoxic T lymphocyte activity by a CCL19/macrophage inflammatory protein (MIP)-3beta antagonist.

Pilkington KR, Clark-Lewis I, McColl SR.

J Biol Chem. 2004 Sep 24;279(39):40276-82. Epub 2004 Jul 1.

9.

Post-onset inhibition of murine arthritis using combined chemokine antagonist therapy.

Gong JH, Yan R, Waterfield JD, Clark-Lewis I.

Rheumatology (Oxford). 2004 Jan;43(1):39-42. Epub 2003 Oct 17.

PMID:
14566030
10.

HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration.

Zhang K, McQuibban GA, Silva C, Butler GS, Johnston JB, Holden J, Clark-Lewis I, Overall CM, Power C.

Nat Neurosci. 2003 Oct;6(10):1064-71. Epub 2003 Sep 21.

11.

The gammaherpesvirus chemokine binding protein binds to the N terminus of CXCL8.

Webb LM, Clark-Lewis I, Alcami A.

J Virol. 2003 Aug;77(15):8588-92.

12.
13.

Eotaxin-3 is a natural antagonist for CCR2 and exerts a repulsive effect on human monocytes.

Ogilvie P, Paoletti S, Clark-Lewis I, Uguccioni M.

Blood. 2003 Aug 1;102(3):789-94. Epub 2003 Apr 10.

PMID:
12689946
15.

Unmasking ligand binding motifs: identification of a chemokine receptor motif by NMR studies of antagonist peptides.

Booth V, Slupsky CM, Clark-Lewis I, Sykes BD.

J Mol Biol. 2003 Mar 21;327(2):329-34.

PMID:
12628240
16.

Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines.

Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, Clark-Lewis I, Borlat F, Wells TN, Kosco-Vilbois MH.

Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1885-90. Epub 2003 Feb 5.

17.

A highly selective CCR2 chemokine agonist encoded by human herpesvirus 6.

Lüttichau HR, Clark-Lewis I, Jensen PØ, Moser C, Gerstoft J, Schwartz TW.

J Biol Chem. 2003 Mar 28;278(13):10928-33. Epub 2003 Jan 27.

18.

Discovery of chemokine substrates for matrix metalloproteinases by exosite scanning: a new tool for degradomics.

Overall CM, McQuibban GA, Clark-Lewis I.

Biol Chem. 2002 Jul-Aug;383(7-8):1059-66. Review.

PMID:
12437088
20.

Structure-function relationship between the human chemokine receptor CXCR3 and its ligands.

Clark-Lewis I, Mattioli I, Gong JH, Loetscher P.

J Biol Chem. 2003 Jan 3;278(1):289-95. Epub 2002 Nov 1.

21.

The CXCR3 binding chemokine IP-10/CXCL10: structure and receptor interactions.

Booth V, Keizer DW, Kamphuis MB, Clark-Lewis I, Sykes BD.

Biochemistry. 2002 Aug 20;41(33):10418-25.

PMID:
12173928
22.

Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo.

McQuibban GA, Gong JH, Wong JP, Wallace JL, Clark-Lewis I, Overall CM.

Blood. 2002 Aug 15;100(4):1160-7.

PMID:
12149192
23.
24.

Tissue-specific mechanisms control the retention of IL-8 in lungs and skin.

Frevert CW, Goodman RB, Kinsella MG, Kajikawa O, Ballman K, Clark-Lewis I, Proudfoot AE, Wells TN, Martin TR.

J Immunol. 2002 Apr 1;168(7):3550-6.

25.
26.

Conserved tryptophan in cytochrome c: importance of the unique side-chain features of the indole moiety.

Black KM, Clark-Lewis I, Wallace CJ.

Biochem J. 2001 Nov 1;359(Pt 3):715-20.

27.

Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1.

McQuibban GA, Butler GS, Gong JH, Bendall L, Power C, Clark-Lewis I, Overall CM.

J Biol Chem. 2001 Nov 23;276(47):43503-8. Epub 2001 Sep 24.

28.

Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development.

Kurth I, Willimann K, Schaerli P, Hunziker T, Clark-Lewis I, Moser B.

J Exp Med. 2001 Sep 17;194(6):855-61.

29.

Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5+ T cells.

Kim CH, Rott LS, Clark-Lewis I, Campbell DJ, Wu L, Butcher EC.

J Exp Med. 2001 Jun 18;193(12):1373-81.

30.

Agonistic and antagonistic activities of chemokines.

Loetscher P, Clark-Lewis I.

J Leukoc Biol. 2001 Jun;69(6):881-4. Review.

PMID:
11404371
31.

ATP induces a conformational change in lipid-bound cytochrome c.

Tuominen EK, Zhu K, Wallace CJ, Clark-Lewis I, Craig DB, Rytomaa M, Kinnunen PK.

J Biol Chem. 2001 Jun 1;276(22):19356-62. Epub 2001 Mar 12.

32.

Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5.

Ogilvie P, Bardi G, Clark-Lewis I, Baggiolini M, Uguccioni M.

Blood. 2001 Apr 1;97(7):1920-4.

PMID:
11264152
33.

Rapid inactivation of stromal cell-derived factor-1 by cathepsin G associated with lymphocytes.

Delgado MB, Clark-Lewis I, Loetscher P, Langen H, Thelen M, Baggiolini M, Wolf M.

Eur J Immunol. 2001 Mar;31(3):699-707.

34.

Structure/function of human herpesvirus-8 MIP-II (1-71) and the antagonist N-terminal segment (1-10).

Crump MP, Elisseeva E, Gong J, Clark-Lewis I, Sykes BD.

FEBS Lett. 2001 Feb 2;489(2-3):171-5.

35.

The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3.

Loetscher P, Pellegrino A, Gong JH, Mattioli I, Loetscher M, Bardi G, Baggiolini M, Clark-Lewis I.

J Biol Chem. 2001 Feb 2;276(5):2986-91. Epub 2000 Nov 10.

36.

Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3.

McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM.

Science. 2000 Aug 18;289(5482):1202-6.

37.
38.

Site-specific independent double labeling of proteins with reporter atoms.

Wallace CJ, Clark-Lewis I.

Biochem Cell Biol. 2000;78(2):79-86.

PMID:
10874468
39.

NMR studies of active N-terminal peptides of stromal cell-derived factor-1. Structural basis for receptor binding.

Elisseeva EL, Slupsky CM, Crump MP, Clark-Lewis I, Sykes BD.

J Biol Chem. 2000 Sep 1;275(35):26799-805.

40.

Synthesis of chemokines.

Clark-Lewis I.

Methods Mol Biol. 2000;138:47-63. No abstract available.

PMID:
10840742
41.

Human CC chemokine I-309, structural consequences of the additional disulfide bond.

Keizer DW, Crump MP, Lee TW, Slupsky CM, Clark-Lewis I, Sykes BD.

Biochemistry. 2000 May 23;39(20):6053-9.

PMID:
10821677
42.

Cutting edge: identification of the orphan receptor G-protein-coupled receptor 2 as CCR10, a specific receptor for the chemokine ESkine.

Jarmin DI, Rits M, Bota D, Gerard NP, Graham GJ, Clark-Lewis I, Gerard C.

J Immunol. 2000 Apr 1;164(7):3460-4.

43.
44.

ESkine, a novel beta-chemokine, is differentially spliced to produce secretable and nuclear targeted isoforms.

Baird JW, Nibbs RJ, Komai-Koma M, Connolly JA, Ottersbach K, Clark-Lewis I, Liew FY, Graham GJ.

J Biol Chem. 1999 Nov 19;274(47):33496-503.

45.

Backbone dynamics of the human CC chemokine eotaxin: fast motions, slow motions, and implications for receptor binding.

Crump MP, Spyracopoulos L, Lavigne P, Kim KS, Clark-lewis I, Sykes BD.

Protein Sci. 1999 Oct;8(10):2041-54.

46.

Characterization of an activated ribosomal S6 kinase variant from maturing sea star oocytes: association with phosphatase 2A and substrate specificity.

Charlton LA, Sayed M, Clark-Lewis I, Aebersold R, Pelech SL.

J Cell Biochem. 1999 Nov 1;75(2):310-26.

PMID:
10502303
47.

Spectroscopic characterization of chemokines: relevance for quality control and standardization.

Rajarathnam K, Crump MP, Clark-Lewis I, Sykes BD.

Dev Biol Stand. 1999;97:49-57.

PMID:
10463530
48.
49.

Cutting edge: RANTES regulates Fas ligand expression and killing by HIV-specific CD8 cytotoxic T cells.

Hadida F, Vieillard V, Mollet L, Clark-Lewis I, Baggiolini M, Debré P.

J Immunol. 1999 Aug 1;163(3):1105-9.

50.

Disulfide bridges in interleukin-8 probed using non-natural disulfide analogues: dissociation of roles in structure from function.

Rajarathnam K, Sykes BD, Dewald B, Baggiolini M, Clark-Lewis I.

Biochemistry. 1999 Jun 15;38(24):7653-8.

PMID:
10387004

Supplemental Content

Loading ...
Support Center